Endo-ERN is focused on 8 main thematic groups (MTGs) which cover rare and/or complex endocrine conditions
Endo-ERN is a network of 100+ Reference Centres (RCs) in 27 EU member states+Norway that offers access to clinical experts for patients with rare endocrine conditions.
Endo-ERN is the network for rare endocrine conditions providing healthcare professionals with access to a variety of resources to support patient care.
If you work at a member institution this page will help with your Endo-ERN contributions.
Access to rare disease expertise without the need to travel is a core ERN objective. Our ePAGs contribute to all Endo-ERN activities.
Some of the supporting documents provide further detail on this topic, offering additional guidance and information.
If your hospital is a member of Endo-ERN or any ERN, first confirm with your HCP representative/DPO/ rare disease office if permission to use CPMS 2.0 has already been granted.
If your hospital does NOT yet have permission to use CPMS or your DPO has not been contacted by DG Sante, please contact the CPMS helpdesk for further support.
Please note: If your hospital is a member any/more than one ERN this does not require any additional action as your Data Protection Officer (DPO) only has to assess the need for a new Data Privacy Impact Assessment (DPIA) once.
Each hospital must assess the need to carry out a Data Privacy Impact Assessment (DPIA). This can be based on if your HCP has used CPMS previously.
Members and affiliated partners that ALREADY USE CPMS may choose to update an existing DPIA performed by their hospital, according to the guidelines of their respective national data privacy authorities. If this applies to your hospital, you will need to assess if a revision to that DPIA is needed. In most cases it is not, as the processing activities in the hospital did not change, however, it is up to the hospital to assess and decide.
Members and affiliated partners that NEVER used CPMS must assess the need of carrying out a DPIA on their activities related to the use of CPMS, according to the guidelines of their respective national data privacy authorities and, if considered necessary, carry out the DPIA.